Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$24.66 - $34.8 $1.93 Million - $2.72 Million
78,207 Added 1304.54%
84,202 $2.92 Million
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $130,631 - $192,739
5,995 New
5,995 $173,000
Q1 2023

May 15, 2023

BUY
$10.78 - $25.38 $145,228 - $341,919
13,472 Added 26.16%
64,978 $1.49 Million
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $239,030 - $362,768
32,477 Added 170.67%
51,506 $561,000
Q2 2022

Aug 15, 2022

SELL
$7.06 - $25.52 $64,295 - $232,410
-9,107 Reduced 32.37%
19,029 $151,000
Q1 2022

May 16, 2022

BUY
$23.34 - $36.08 $643,950 - $995,447
27,590 Added 5053.11%
28,136 $666,000
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $10,066 - $21,184
-571 Reduced 51.12%
546 $19,000
Q3 2021

Nov 15, 2021

SELL
$12.95 - $49.69 $36,039 - $138,287
-2,783 Reduced 71.36%
1,117 $20,000
Q2 2021

Aug 16, 2021

SELL
$25.57 - $44.88 $276,156 - $484,704
-10,800 Reduced 73.47%
3,900 $175,000
Q1 2021

May 17, 2021

BUY
$19.02 - $31.15 $279,594 - $457,905
14,700 New
14,700 $381,000
Q3 2020

Nov 16, 2020

SELL
$15.19 - $22.4 $335,471 - $494,703
-22,085 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$6.19 - $18.84 $136,706 - $416,081
22,085 New
22,085 $390,000
Q4 2019

Feb 14, 2020

SELL
$4.69 - $13.45 $103,142 - $295,792
-21,992 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$9.41 - $16.56 $206,944 - $364,187
21,992 New
21,992 $264,000
Q2 2018

Aug 14, 2018

SELL
$5.99 - $9.1 $69,442 - $105,496
-11,593 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$8.46 - $23.08 $70,446 - $192,187
8,327 Added 254.96%
11,593 $100,000
Q4 2017

Feb 14, 2018

BUY
$14.47 - $20.8 $47,259 - $67,932
3,266
3,266 $68,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.